WO1996003929A1 - Procede de prediction d'un accouchement premature a l'aide d'estetrol (e4) comme indicatuer - Google Patents

Procede de prediction d'un accouchement premature a l'aide d'estetrol (e4) comme indicatuer Download PDF

Info

Publication number
WO1996003929A1
WO1996003929A1 PCT/US1995/003442 US9503442W WO9603929A1 WO 1996003929 A1 WO1996003929 A1 WO 1996003929A1 US 9503442 W US9503442 W US 9503442W WO 9603929 A1 WO9603929 A1 WO 9603929A1
Authority
WO
WIPO (PCT)
Prior art keywords
concentration
estetrol
body fluid
tocolytic
treatment
Prior art date
Application number
PCT/US1995/003442
Other languages
English (en)
Inventor
Vivian Dullien
Original Assignee
Biex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biex, Inc. filed Critical Biex, Inc.
Priority to AU21034/95A priority Critical patent/AU2103495A/en
Publication of WO1996003929A1 publication Critical patent/WO1996003929A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/42—Gynaecological or obstetrical instruments or methods

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un procédé de prédiction et de détection du début des contractions d'une femme enceinte consiste à analyser un fluide corporel de la patiente afin de déterminer la concentration en estétrol; à mettre en corrélation cette concentration avec une valeur étalon; et à mettre en relation une concentration plus élevée d'estétrol par rapport à la valeur étalon afin d'obtenir une indication sur l'éventualité d'un accouchement prématuré. La valeur étalon est généralement sélectionnée dans le groupe comprenant (1) une plage prédéterminée de concentrations d'estétrol dans le fluide corporel chez des femmes enceintes normales à un moment présélectionné par rapport à un accouchement normal à terme, ou (2) une concentration d'estétrol mesurée antérieurement du même fluide corporel de la même femme enceinte. L'invention concerne également un procédé de contrôle d'une thérapie tocolytique qui consiste à déterminer une première concentration d'estétrol dans un fluide corporel d'une femme enceinte soumise à un traitement avec un agent tocolytique ou à qui on prescrit un tel traitement et, en se basant sur la valeur de la première concentration par rapport à une valeur étalon, commencer, continuer, arrêter ou modifier le traitement.
PCT/US1995/003442 1994-08-04 1995-03-17 Procede de prediction d'un accouchement premature a l'aide d'estetrol (e4) comme indicatuer WO1996003929A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21034/95A AU2103495A (en) 1994-08-04 1995-03-17 Method for prediction of premature delivery using estetrol (e4) as an indicator

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28579694A 1994-08-04 1994-08-04
US08/285,796 1994-08-04

Publications (1)

Publication Number Publication Date
WO1996003929A1 true WO1996003929A1 (fr) 1996-02-15

Family

ID=23095728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/003442 WO1996003929A1 (fr) 1994-08-04 1995-03-17 Procede de prediction d'un accouchement premature a l'aide d'estetrol (e4) comme indicatuer

Country Status (2)

Country Link
AU (1) AU2103495A (fr)
WO (1) WO1996003929A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174665B1 (en) 1999-09-10 2001-01-16 Biex, Inc. Hormone replacement therapy monitoring
WO2001020339A1 (fr) * 1999-09-10 2001-03-22 Biex, Inc. Surveillance d'un traitement hormonal substitutif
EP1260225A1 (fr) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Compositions pharmaceutiques pour le traitement hormonal substitutif
WO2002094276A1 (fr) * 2001-05-18 2002-11-28 Pantarhei Bioscience B.V. Composition pharmaceutique a utiliser en therapie de remplacement d'hormones
US6556977B1 (en) 1997-08-14 2003-04-29 Adeza Biomedical Corporation Methods for selecting, developing and improving diagnostic tests for pregnancy-related conditions
WO2009011576A1 (fr) * 2007-07-19 2009-01-22 Pantarhei Bioscience B.V. Traitement ou prévention de troubles de l'hypertension de grossesse ou d'un retard de croissance fœtal
US7732430B2 (en) 2001-05-23 2010-06-08 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
US7776557B2 (en) * 2006-01-30 2010-08-17 Diagnostic Technologies Ltd. Method for monitoring tocolytic treatment
US7871995B2 (en) 2001-05-23 2011-01-18 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
US7923440B2 (en) 2002-06-11 2011-04-12 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
US7943604B2 (en) 2002-06-11 2011-05-17 Pantarhei Bioscience B.V. Method of treating human skin and a skin care composition for use in such a method
US8026228B2 (en) 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US8236785B2 (en) 2007-01-08 2012-08-07 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
US8987240B2 (en) 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
US9034854B2 (en) 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US11452733B2 (en) 2018-04-19 2022-09-27 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
US11484539B2 (en) 2018-04-19 2022-11-01 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
US11793760B2 (en) 2015-06-18 2023-10-24 Estetra Srl Orodispersible dosage unit containing an estetrol component
US11896602B2 (en) 2016-08-05 2024-02-13 Estetra Srl Method for preventing pregnancy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028535A (en) * 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5081013A (en) * 1987-08-14 1992-01-14 Boehringer Biochemia Robin S.P.A. Immunodiagnostic device and method
US5096830A (en) * 1987-11-17 1992-03-17 Adeza Biomedical Corporation Preterm labor and membrane rupture test
US5370135A (en) * 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081013A (en) * 1987-08-14 1992-01-14 Boehringer Biochemia Robin S.P.A. Immunodiagnostic device and method
US5096830A (en) * 1987-11-17 1992-03-17 Adeza Biomedical Corporation Preterm labor and membrane rupture test
US5028535A (en) * 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5370135A (en) * 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRITISH MEDICAL JOURNAL, Volume 294, issued 31 January 1987, J. DARNE et al., "Increased Saliva Oestriol to Progesterone Ratio before Idiopathic Preterm Delivery: A Possible Predictor for Preterm Labour?", pages 270-272. *
H.W. TAEUSCH et al., "Schaffer and Avery's Diseases of the Newborn", Published 1991, by W.B. SAUNDERS CO. (PHILADELPHIA), pages 87-92. *
J.D. WILSON, "Williams Textbook of Endocrinology", Published 1985, by W.B. SAUNDERS CO. (PHILADELPHIA), pages 422-437. *
J.R. SCOTT et al., "Danforth's Obstetrics and Gynecology", Published 1990, by J.B. LIPPINCOTT CO. (PHILADELPHIA), pages 335-351. *
JOURNAL OF CHROMATOGRAPHY, Volume 568, issued 1991, J. NOMA et al., "Automated Direct High-Performance Liquid Chromatographic Assay for Estetrol, Estriol, Cortisone and Cortisol in Serum and Amniotic Fluid", pages 35-44. *
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, Volume 40, Number 4, issued 1975, D. TULCHINSKY et al., "Plasma Estetrol as an Index of Fetal Well-Being", pages 560-567. *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6556977B1 (en) 1997-08-14 2003-04-29 Adeza Biomedical Corporation Methods for selecting, developing and improving diagnostic tests for pregnancy-related conditions
US7228295B2 (en) 1997-08-14 2007-06-05 Adeza Biomedical Corporation Methods for selecting, developing and improving diagnostic tests for pregnancy-related conditions
WO2001020339A1 (fr) * 1999-09-10 2001-03-22 Biex, Inc. Surveillance d'un traitement hormonal substitutif
US6174665B1 (en) 1999-09-10 2001-01-16 Biex, Inc. Hormone replacement therapy monitoring
EP1700602A1 (fr) * 2001-05-18 2006-09-13 Pantarhei Bioscience B.V. Composition pharmaceutique à utiliser en thérapie de remplacement d'hormones
WO2002094276A1 (fr) * 2001-05-18 2002-11-28 Pantarhei Bioscience B.V. Composition pharmaceutique a utiliser en therapie de remplacement d'hormones
WO2002094275A1 (fr) * 2001-05-18 2002-11-28 Pantarhei Bioscience B.V. Utilisation de composes d'oestrogene pour accroitre la libido chez les femmes
EP1260225A1 (fr) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Compositions pharmaceutiques pour le traitement hormonal substitutif
US8048869B2 (en) * 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
US7723320B2 (en) 2001-05-18 2010-05-25 Pantarhei Bioscience B.V. Use of estrogen compounds to increase libido in women
US7732430B2 (en) 2001-05-23 2010-06-08 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
US7871995B2 (en) 2001-05-23 2011-01-18 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
US8026228B2 (en) 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US7943604B2 (en) 2002-06-11 2011-05-17 Pantarhei Bioscience B.V. Method of treating human skin and a skin care composition for use in such a method
US7923440B2 (en) 2002-06-11 2011-04-12 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
US9040509B2 (en) 2002-06-11 2015-05-26 Pantarhei Bioscience B.V. Method of treating human skin and a skin care composition for use in such a method
US10201611B2 (en) 2002-07-12 2019-02-12 Donesta Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US9034854B2 (en) 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US9561238B2 (en) 2002-10-23 2017-02-07 Donesta Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
US8987240B2 (en) 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
US7776557B2 (en) * 2006-01-30 2010-08-17 Diagnostic Technologies Ltd. Method for monitoring tocolytic treatment
US8236785B2 (en) 2007-01-08 2012-08-07 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
US8518923B2 (en) 2007-07-19 2013-08-27 Pantarhei Bioscience B.V. Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation
WO2009011576A1 (fr) * 2007-07-19 2009-01-22 Pantarhei Bioscience B.V. Traitement ou prévention de troubles de l'hypertension de grossesse ou d'un retard de croissance fœtal
US11793760B2 (en) 2015-06-18 2023-10-24 Estetra Srl Orodispersible dosage unit containing an estetrol component
US11964055B2 (en) 2015-06-18 2024-04-23 Estetra Srl Orodispersible dosage unit containing an estetrol component
US11896602B2 (en) 2016-08-05 2024-02-13 Estetra Srl Method for preventing pregnancy
US11452733B2 (en) 2018-04-19 2022-09-27 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
US11484539B2 (en) 2018-04-19 2022-11-01 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
US11666585B2 (en) 2018-04-19 2023-06-06 Estetra Srl Compounds and their uses for alleviating menopause-associated symptoms

Also Published As

Publication number Publication date
AU2103495A (en) 1996-03-04

Similar Documents

Publication Publication Date Title
EP0723666B1 (fr) Utilisation du dosage d' estriol dans le controle d'une therapie tocolytique
WO1996003929A1 (fr) Procede de prediction d'un accouchement premature a l'aide d'estetrol (e4) comme indicatuer
Wald et al. Gastrointestinal transit: the effect of the menstrual cycle
EP0663071B1 (fr) Procede de prediction du travail precoce
Rochelson et al. A Rapid Colorimetric AFP Monoclonal Antibody Test for the Diagnosis of Preterrn Rupture of the Membranes
Koullapis et al. Plasma prostanoids in pregnancy‐induced hypertension
Jaatinen et al. Serum total renin is elevated in women with polycystic ovarian syndrome
SE437304B (sv) Forfarande och medel for samtidig bestemning av hormonerna humant korionogonadotropin (hcg) och prolaktin (prl)
WO2007088543A1 (fr) Methode permettant de determiner l'efficacite d'un traitement contre la preeclampsie
Langer et al. Cervico‐vaginal fetal fibronectin: Predictive value during false labor
Egerman et al. Neuropeptide Y and nitrite levels in preeclamptic and normotensive gravid women
McCoshen et al. Prostaglandin E2 release on the fetal and maternal sides of the amnion and chorion-decidua before and after term labor
Richardson A new biochemical test for pregnancy: A study of 2,560 tests on 1,640 patients
Hayashi et al. Prospective study of angiotensin II response to positional change in pregnancy-induced hypertension
AU1330800A (en) Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
RU2138805C1 (ru) СПОСОБ ОЦЕНКИ АДРЕНОРЕАКТИВНОСТИ ЭРИТРОЦИТОВ БЕРЕМЕННЫХ ЖЕНЩИН ПО ИЗМЕНЕНИЮ СКОРОСТИ ОСЕДАНИЯ ЭРИТРОЦИТОВ КАПИЛЛЯРНОЙ КРОВИ НА ФОНЕ БЛОКАДЫ ИХ βАДРЕНОРЕЦЕПТОРОВ ОБЗИДАНОМ
SOMA et al. Maternal-to-fetal transfer of ritodrine in twin pregnancy
Shukhratovna Predictors of Diagnosis of Emerging Polycystic Ovary Syndrome in Adolescent Girls
Pelkonen et al. Placental transfer of clenbuterol early in human pregnancy
Lateef Thyroid Hormone Changes in Early Pregnancy Bleeding Versus Normal Healthy Pregnancy
Thangam Study on Role of Thyroid Dysfunction in Women with Menstrual Disorders
Harshitha Relationship between Serum Ferritin and Gestational Diabetes Mellitus
Ayhan et al. Digoxin-like immunoreactive substance and preterm labor
Nivya Premkumari Study of Association of Thyroid Hormone (FT4 and TSH) in Preeclampsia and Normal Pregnancy and Correlate it with Severity of Preeclampsia
RU2181202C1 (ru) Способ дифференцированного определения степени тяжести гестоза беременных

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642